期刊文献+

1例重症肌无力患者的个体化药学服务 被引量:1

Individualized Pharmaceutical Care in One Patient with Myasthenia Gravis
原文传递
导出
摘要 目的:探讨药师如何对重症肌无力患者提供个体化药学服务。方法:临床药师与临床医师密切配合,通过药物基因检测、审查药物相互作用、跟踪治疗药物监测结果、进行患者用药教育等方式,提供药学服务。结果:患者治疗方案调整后,实验室检查无明显异常,他克莫司血药浓度达到正常范围,病情有所改善。结论:临床药师加入临床治疗团队,提供个体化药学服务可以提高临床药物治疗效果。 Objective: To study on the way of pharmacists providing individualized pharmaceutical care to the patients with myasthenia gravis. Methods: Clinical pharmacists provide pharmaceutical care to this patient through detecting the drug-related genes, reviewing drug interactions, therapeutic drug monitoring. Results: After the adjustment of treatment, laboratory examination of the patient was showed no abnormalities, and the blood concentration of tacrolimus was in the normal range. And at the same time, the patient's condition was improved. Conclusion: it is useful in improving the therapeutic effect of clinical medicine with clinical pharmacists joining the clinical team and providing individualized pharmaceutical care.
出处 《临床药物治疗杂志》 2014年第4期39-42,共4页 Clinical Medication Journal
基金 临床药学科国家临床重点专科建设项目(2014-2018年)
关键词 重症肌无力 免疫抑制剂 药物基因检测 治疗药物监测 药物相互作用 myasthenia gravis immunosuppressive agents drug gene detection therapeutic drugmonitoring drug interactions
  • 相关文献

参考文献3

二级参考文献57

  • 1陈业辉,郑克立,陈立中,戴宇平,费继光,王长希,魏鸿蔼,王良圣,胡建波.口服他克莫司血药浓度-时间曲线下面积[J].中华泌尿外科杂志,2004,25(11):750-752. 被引量:10
  • 2彭丹涛,许贤豪,佘子瑜.新斯的明试验改良结果判定法研究[J].中国神经免疫学和神经病学杂志,2007,14(1):1-3. 被引量:26
  • 3许贤豪.重症肌无力[M]//许贤豪主编.肌无力-临床与基础.北京:中国协和医科大学出版社,2003:46-75.
  • 4Wallemacq PE, Verbeeck PK. Comparative clinical pharmaeokimetics of tacrolimus in paediatric and adult patients[J]. Clin Pharmacokinet, 2001, 40 (4): 283-295.
  • 5Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drug in clin- ical practice [J]. Clin Atherapeutics, 2002,24 (3) : 330--350.
  • 6Kalra BS. Cytochrome P450 enzyme isoforms and their therapeutic implications: an update[J]. Indian .1 Med Sci, 2007, 61(2): 102-116.
  • 7Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A mediated metabolism[J]. Adv Drug Deliv Rev, 2002, 54 (10): 1271-1294.
  • 8Min DI, Ellingrod VL. Association of the CYP3A4^+ 1B 5-flanking region polymorphism with cyclospo- rine pharmacokinetics in healthy subjects[J]. Ther Drug Monit, 2003, 25(3): 305-309.
  • 9周宏灏.细胞色素P450药物代谢酶的遗传药理学进展.药理学进展,2000,19(2):87-90.
  • 10Hesselink DA, Schaik RH, Heiden IP, et al. Ge netic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calci- neurin inhibitors cyclosporine and tacrolimus [J]. Clin Pharmacol Ther, 2003, 74(3): 245-254.

共引文献195

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部